GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genprex Inc (NAS:GNPX) » Definitions » Cash Ratio

Genprex (Genprex) Cash Ratio : 2.07 (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Genprex Cash Ratio?

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. Genprex's Cash Ratio for the quarter that ended in Dec. 2023 was 2.07.

Genprex has a Cash Ratio of 2.07. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.

The historical rank and industry rank for Genprex's Cash Ratio or its related term are showing as below:

GNPX' s Cash Ratio Range Over the Past 10 Years
Min: 0.19   Med: 7.46   Max: 60.58
Current: 2.07

During the past 9 years, Genprex's highest Cash Ratio was 60.58. The lowest was 0.19. And the median was 7.46.

GNPX's Cash Ratio is ranked worse than
58.48% of 1522 companies
in the Biotechnology industry
Industry Median: 2.93 vs GNPX: 2.07

Genprex Cash Ratio Historical Data

The historical data trend for Genprex's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genprex Cash Ratio Chart

Genprex Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Ratio
Get a 7-Day Free Trial Premium Member Only 3.92 60.58 24.37 7.46 2.07

Genprex Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.46 3.74 2.58 2.70 2.07

Competitive Comparison of Genprex's Cash Ratio

For the Biotechnology subindustry, Genprex's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genprex's Cash Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genprex's Cash Ratio distribution charts can be found below:

* The bar in red indicates where Genprex's Cash Ratio falls into.



Genprex Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

Genprex's Cash Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash Ratio (A: Dec. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=6.738/3.254
=2.07

Genprex's Cash Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash Ratio (Q: Dec. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=6.738/3.254
=2.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Genprex  (NAS:GNPX) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.


Genprex Cash Ratio Related Terms

Thank you for viewing the detailed overview of Genprex's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Genprex (Genprex) Business Description

Traded in Other Exchanges
Address
3300 Bee Cave Road, Suite 650-227, Austin, TX, USA, 78746
Genprex Inc is a clinical-stage gene therapy company. It is a clinical stage gene therapy company pioneering the development of gene-based therapies for large patient populations with unmet medical needs.
Executives
Catherine M Vaczy officer: EVP & Chief Strategy Officer C/O PHASE III MEDICAL, INC., 330 SOUTH SERVICE ROAD, SUITE 120, MELVILLE NY 11747
John Rodney Varner director, 10 percent owner, officer: Chief Executive Officer P.O. BOX 162341, AUSTIN TX 78716
Hermant Kumar officer: Chief Mfgr & Tech Officer 3300 BEE CAVE ROAD, #650-227, AUSTIN TX 78746
Mark Stanley Berger officer: Chief Medical Officer 140 RIVERSIDE DRIVE, APT. 9K, NEW YORK NY 10024
Brent M Longnecker director C/O RESOURCES CONNECTION, 695 TOWN CENTER DR, COSTA MESA CA 92626
Moreno Toscano Jose Antonio director 1501 UNIVERSITY CLUB DRIVE, AUSTIN TX 78732
Wilson William R Jr. director 1407 ETHRIDGE AVE, AUSTIN TX 78703
Michael Thomas Redman officer: EVP & Chief Operating Officer 16402 EMILIA COURT, SPRING TX 77379
John N Bonfiglio director C/O MICROLIN BIO, INC., NEW YORK NY 10022
Genprex, Inc. director, 10 percent owner, officer: Chief Executive Officer 1601 TRINITY STREET, BLDG. B, SUITE 3.322, AUSTIN TX 78712
Julien L Pham officer: Chief Operating Officer 944 DORCHESTER AVE #56, BOSTON MA 02125
Jack A Roth 10 percent owner 6516 BROMPTON ROAD, HOUSTON TX 770055
Christy M. Nance 10 percent owner 8305 SCENIC RIDGE COVE, AUSTIN TX 78735
Ryan M. Confer officer: Chief Financial Officer 1000 SAN MARCOS ST. #460, AUSTIN TX 78702
Robert W. Pearson director 3001 MEANDERING RIVER COURT, AUSTIN TX 78746

Genprex (Genprex) Headlines

From GuruFocus